Interleukin-34: A Potential Diagnostic and Therapeutic Target for Rheumatoid Arthritis

He, Wei; Xu, Xiao-Di; Dong, Yi-Man; Wu, Hua

doi:10.3899/jrheum.141135

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, IL‐34 and/or CSF‐1R suppression attenuate the severity of inflammatory arthritis in animal models . These results support the targeting of IL‐34/CSF‐1R as a potentially effective therapy for RA . However, interventions for blocking IL‐34 should be considered in terms of not only beneficial effects but also the risk of potential detrimental consequences for the host.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Functions of interleukin‐34 and its emerging association with rheumatoid arthritis

Zhou

Xie

et al. 2016

Immunology

View full text Add to dashboard Cite

SummaryRheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic, synovial inflammation affecting multiple joints, finally leading to extra-articular lesions for which limited effective treatment options are currently available. Interleukin-34 (IL-34), recently discovered as the second colony-stimulating factor-1 receptor (CSF-1R) ligand, is a newly discovered cytokine. Accumulating evidence has disclosed crucial roles of IL-34 in the proliferation and differentiation of mononuclear phagocyte lineage cells, osteoclastogenesis and inflammation. Recently, IL-34 was detected at high levels in patients with active RA and in experimental models of inflammatory arthritis. Blockade of functional IL-34 with a specific monoclonal antibody can reduce the severity of inflammatory arthritis, suggesting that targeting IL-34 or its receptors may constitute a novel therapeutic strategy for autoimmune diseases such as RA. Here, we have comprehensively discussed the structure and biological functions of IL-34, and reviewed recent advances in our understanding of the emerging role of IL-34 in the development of RA as well as its potential utility as a therapeutic target.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Functions of interleukin‐34 and its emerging association with rheumatoid arthritis

Zhou

Xie

et al. 2016

Immunology

View full text Add to dashboard Cite

show abstract

“…It has been revealed that IL-34 expression increases in the synovium, serum, and SF of RA patients and is associated with RF and anticyclic citrullinated peptide (CCP) antibody titers [14,25]. A significant role of IL-34 in RA synovitis has been suggested, [26] and functionally isolated RA-derived fibroblast-like synoviocytes and osteoblasts were found to produce IL-34 in response to TNF-α [16].…”

Section: Discussionmentioning

confidence: 99%

Interleukin-34 in the Serum and Synovial Fluid of Rheumatoid Arthritis Patients: Relation to Disease Activity and Radiographic Damage

et al. 2018

View full text Add to dashboard Cite

Background Interleukin 34 (IL-34) is a recently discovered proinflammatory cytokine that can promote inflammation and osteoclastogenesis in arthritic joints. In this study, we tried to assess the serum and synovial fluid (SF) levels of IL-34 in rheumatoid arthritis (RA) patients, and to determine its relationship with disease activity and radiographic damage. Patients and methods ELISA was used to evaluate IL-34 levels in the serum of RA patients (n=50), osteoarthritis (OA) patients (n=28), and healthy control subjects (n=20) and in SF isolated from RA and OA patients. Disease activity in RA patients was assessed using the disease activity score-28 (DAS 28). The extent of radiographic joint damage, narrowing, and erosions was assessed. Results Serum IL-34 level was significantly elevated in RA patients compared to that in OA patients and healthy controls (P<0.0001). Synovial IL-34 level was also significantly elevated in RA patients compared to that in OA patients (P=0.0004). Serum and synovial IL-34 levels were significantly higher in cases that were rheumatoid factor (RF) positive (n=28) compared to the levels in RF-negative RA cases (n=22) (P=0.03 and P=0.04, respectively). Serum and synovial IL-34 levels were positively correlated with RF (r=0.43, P=0.02 and r=0.39, P=0.03, respectively), and with the extent of radiological damage (SENS) (P=0.0002 and P<0.0001, respectively). However, no significant correlation between IL-34 levels and disease activity was found. Conclusion IL-34 appears to play a key role in the pathogenesis of RA and contribute to bone destruction, making it a potential therapeutic target in the management armamentarium of the disease.

show abstract

Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications

Kumari

Silakari

Singh

2018

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Interleukin-34: A Potential Diagnostic and Therapeutic Target for Rheumatoid Arthritis

Cited by 4 publications

References 9 publications

Functions of interleukin‐34 and its emerging association with rheumatoid arthritis

Functions of interleukin‐34 and its emerging association with rheumatoid arthritis

Interleukin-34 in the Serum and Synovial Fluid of Rheumatoid Arthritis Patients: Relation to Disease Activity and Radiographic Damage

Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications

Contact Info

Product

Resources

About